NEUROPROTECTIVE PROPERTIES OF WITHANIA SOMNIFERA - THERAPEUTIC POTENTIAL IN ALZHEIMER'S AND PARKINSON'S DISEASE
Abstract
Introduction: Withania somnifera (ashwagandha) is a medicinal plant known for its adaptogenic, anti-inflammatory and neuroprotective properties. The withanolides it contains have antioxidant and neuroplasticity-enhancing effects, making it a potential aid in the treatment of neurodegenerative diseases such as Alzheimer's and Parkinson's.
Aim of the study: The aim of this literature review was to analyse the mechanisms of action of Withania somnifera and to evaluate its potential efficacy and safety in the context of adjunctive therapy in neurodegenerative diseases.
Material and methods: The search was conducted in the PubMed database. Most of the publications from the last 10 years were included, covering in vitro, in vivo and clinical studies. The following keywords and MeSH terms were used: ‘Withania somnifera’, “Ashwagandha”, ‘Alzheimer's disease’, ‘Parkinson's disease’, ‘neuroprotection’.
Results: The analysed preclinical and clinical studies indicate a positive effect of Withania somnifera on cognitive and motor functions, reduction of oxidative stress and inhibition of inflammatory and apoptotic processes in the central nervous system. These data suggest the possibility of using ashwagandha as an adjunct in the treatment of neurodegeneration.
Conclusions: Although the results of previous studies are promising, further high-quality randomised clinical trials are needed to confirm the efficacy and safety of Withania somnifera in the treatment of Alzheimer's and Parkinson's disease.
References
Alzheimer's disease facts and figures. Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002 Jul 19;297(5580):353-6. doi: 10.1126/science.1072994.
Zahiruddin S, Basist P, Parveen A, Parveen R, Khan W, Gaurav, Ahmad S. Ashwagandha in brain disorders: A review of recent developments. J Ethnopharmacol. 2020 Jul 15;257:112876. doi: 10.1016/j.jep.2020.112876.
Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8;25(24):5789. doi: 10.3390/molecules25245789.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948.
Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021 May;20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2.
Sveinbjornsdottir S. The clinical symptoms of Parkinson's disease. J Neurochem. 2016 Oct;139 Suppl 1:318-324. doi: 10.1111/jnc.13691.
Fox SH, Katzenschlager R, Lim SY, Ravina B, Seppi K, Coelho M, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2011 Oct;26 Suppl 3:S2-41. doi: 10.1002/mds.23829.
Dias V, Junn E, Mouradian MM. The role of oxidative stress in Parkinson's disease. J Parkinsons Dis. 2013;3(4):461-91. doi: 10.3233/JPD-130230.
Bhat JA, Akther T, Najar RA, Rasool F, Hamid A. Withania somnifera (L.) Dunal (Ashwagandha); current understanding and future prospect as a potential drug candidate. Front Pharmacol. 2022 Dec 12;13:1029123. doi: 10.3389/fphar.2022.1029123.
Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208-13. doi: 10.4314/ajtcam.v8i5S.9.
Mirjalili MH, Moyano E, Bonfill M, Cusido RM, Palazón J. Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules. 2009 Jul 3;14(7):2373-93. doi: 10.3390/molecules14072373.
Gaurav H, Yadav D, Maurya A, Yadav H, Yadav R, Shukla AC, Sharma M, Gupta VK, Palazon J. Biodiversity, Biochemical Profiling, and Pharmaco-Commercial Applications of Withania somnifera: A Review. Molecules. 2023 Jan 26;28(3):1208. doi: 10.3390/molecules28031208.
Chandrasekhar K, Kapoor J, Anishetty S. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root in reducing stress and anxiety in adults. Indian J Psychol Med. 2012 Jul;34(3):255-62. doi: 10.4103/0253-7176.106022.
Gupta M, Kaur G. Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. J Neuroinflammation. 2016 Aug 22;13(1):193. doi: 10.1186/s12974-016-0650-3.
Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1093-105. doi: 10.1016/j.pnpbp.2007.09.011.
Sun GY, Li R, Cui J, Hannink M, Gu Z, Fritsche KL, Lubahn DB, Simonyi A. Withania somnifera and Its Withanolides Attenuate Oxidative and Inflammatory Responses and Up-Regulate Antioxidant Responses in BV-2 Microglial Cells. Neuromolecular Med. 2016 Sep;18(3):241-52. doi: 10.1007/s12017-016-8411-0.
Kuboyama T, Tohda C, Komatsu K. Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol. 2005 Apr;144(7):961-71. doi: 10.1038/sj.bjp.0706122.
Mikulska P, Malinowska M, Ignacyk M, Szustowski P, Nowak J, Pesta K, Szeląg M, Szklanny D, Judasz E, Kaczmarek G, Ejiohuo OP, Paczkowska-Walendowska M, Gościniak A, Cielecka-Piontek J. Ashwagandha (Withania somnifera)-Current Research on the Health-Promoting Activities: A Narrative Review. Pharmaceutics. 2023 Mar 24;15(4):1057. doi: 10.3390/pharmaceutics15041057.
Butterfield DA, Halliwell B. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat Rev Neurosci. 2019 Mar;20(3):148-160. doi: 10.1038/s41583-019-0132-6.
Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, Khanna P, Jain SC, Thakur SS, Ravindranath V. Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver. Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):3510-5. doi: 10.1073/pnas.1112209109.
Visweswari, G.; Christopher, R.; Rajendra, W. Withania Somnifera Against Glutamate Excitotoxicity and Neuronal Cell Loss in a Scopolamine-Induced Rat Model of Alzheimer’s Disease. European Journal of Biological Research 2021, 11, 156-167.
Pingali U, Pilli R, Fatima N. Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Res. 2014 Jan;6(1):12-8. doi: 10.4103/0974-8490.122912.
Choudhary D, Bhattacharyya S, Bose S. Efficacy and Safety of Ashwagandha (Withania somnifera (L.) Dunal) Root Extract in Improving Memory and Cognitive Functions. J Diet Suppl. 2017 Nov 2;14(6):599-612. doi: 10.1080/19390211.2017.1284970.
Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015;386(9996):896–912.
Sankar SR, Manivasagam T, Krishnamurti A, Ramanathan M. The neuroprotective effect of Withania somnifera root extract in MPTP-intoxicated mice: an analysis of behavioral and biochemical variables. Cell Mol Biol Lett. 2007;12(4):473-81. doi: 10.2478/s11658-007-0015-0.
Javed H, Nagoor Meeran MF, Azimullah S, Adem A, Sadek B, Ojha SK. Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models. Front Pharmacol. 2019 Mar 19;9:1555. doi: 10.3389/fphar.2018.01555.
Fanibunda SE, Kukkemane K, Ghai U, Kolthur-Seetharam U, Hingorani L, Vaidya ADB, Vaidya VA. Withania somnifera Regulates Mitochondrial Biogenesis and Energetics in Rat Cortical Neurons: Role of BDNF and SIRT1. Mol Neurobiol. 2025 Aug;62(8):10277-10295. doi: 10.1007/s12035-025-04920-7.
Ahmad M, Saleem S, Ahmad AS, Ansari MA, Yousuf S, Hoda MN, Islam F. Neuroprotective effects of Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. Hum Exp Toxicol. 2005 Mar;24(3):137-47. doi: 10.1191/0960327105ht509oa.
Shan CS, Zhang HF, Xu QQ, Shi YH, Wang Y, Li Y, Lin Y, Zheng GQ. Herbal Medicine Formulas for Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Double-Blind Placebo-Controlled Clinical Trials. Front Aging Neurosci. 2018 Nov 8;10:349. doi: 10.3389/fnagi.2018.00349.
Tandon N, Yadav SS. Safety and clinical effectiveness of Withania Somnifera (Linn.) Dunal root in human ailments. J Ethnopharmacol. 2020 Jun 12;255:112768. doi: 10.1016/j.jep.2020.112768.
Views:
13
Downloads:
9
Copyright (c) 2025 Weronika Sobota, Przemysław Piskorz, Patryk Biesaga, Olaf Jadanowski, Kamil Łebek, Alicja Bury, Daria Litworska-Sójka, Bartosz Komsta, Julia Lipiec, Wojciech Pabis
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
